WO2012052843A1 - Dérivés de pochoxime convenant pour le traitement de pathologies en rapport avec hsp90 - Google Patents

Dérivés de pochoxime convenant pour le traitement de pathologies en rapport avec hsp90 Download PDF

Info

Publication number
WO2012052843A1
WO2012052843A1 PCT/IB2011/002796 IB2011002796W WO2012052843A1 WO 2012052843 A1 WO2012052843 A1 WO 2012052843A1 IB 2011002796 W IB2011002796 W IB 2011002796W WO 2012052843 A1 WO2012052843 A1 WO 2012052843A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
equiv
mmol
group
disease
Prior art date
Application number
PCT/IB2011/002796
Other languages
English (en)
Inventor
Nicolas Winssinger
Sofia Barluenga
Original Assignee
Universite De Strasbourg
Le Centre National De La Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112013009614A priority Critical patent/BR112013009614A2/pt
Application filed by Universite De Strasbourg, Le Centre National De La Recherche Scientifique filed Critical Universite De Strasbourg
Priority to US13/880,878 priority patent/US20140031302A1/en
Priority to JP2013534404A priority patent/JP2013543840A/ja
Priority to AU2011319685A priority patent/AU2011319685B2/en
Priority to KR1020137012551A priority patent/KR20140021520A/ko
Priority to RU2013122898/04A priority patent/RU2013122898A/ru
Priority to CN2011800601830A priority patent/CN103370311A/zh
Priority to CA2812320A priority patent/CA2812320A1/fr
Priority to EP11797116.8A priority patent/EP2630132A1/fr
Publication of WO2012052843A1 publication Critical patent/WO2012052843A1/fr
Priority to IL225371A priority patent/IL225371A0/en
Priority to US14/611,978 priority patent/US20150374680A1/en
Priority to US15/250,742 priority patent/US20170174669A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Definitions

  • the present invention is related to novel derivatives, analogs, and intermediates of the natural products radicicol, pochonins, pochoximes, and to their syntheses.
  • the present invention is also related to the use of these compounds as inhibitors of kinases and of the enzyme family known as heat shock protein 90 (HSP90).
  • the heat shock protein 90 (HSP90) has emerged as an extremely promising therapeutic target in recent years.' 1"3 ' Despite the seemingly ubiquitous functions of this highly expressed chaperone, its role in stabilizing conformational ly labile proteins has implications in diverse pathologies.
  • Inhibitors of HSP90 have been shown to be broadly effective for a number of cancer indications,' 4 ' 51 neurodegenerative diseases,' 6"101 infectious diseases,' 111 and inflammation- related disorders.
  • ' 12 ' Two natural products, radicicol and geldanamycin (as shown in Scheme 1 below), both of which disrupt the ATPase activity of Hsp90, have been instrumental in understanding the role of HSP90 in oncogenic processes and the therapeutic potential of its inhibition.
  • ' 13"15 neither natural product has acceptable pharmacological properties for clinical application.
  • Medicinal chemistry efforts have led to the discovery of novel scaffolds such as purines' 16 ' 171 (CNF-2024), resorcinol-isoxazoles [!
  • dimethoxyhydroquinone functionality has recently been reported to have better pharmacological properties than 17AAG while acting as a prodrug. 125 '
  • pochonin D represents a simplified pharmacophore of radicicol which recapitulates its activity. Furthermore, significant improvements in cellular efficacy could be achieved through the formation of oximes. [27] In fact, pochoximes A, B, and C (as shown in Scheme 1 above), are amongst the most potent HSP90 inhibitors reported to date, inducing client protein degradation in SKBR3 cell lines at low nM concentration, and pochoxime A treatment leads to tumor regression in xenografts bearing BT474 breast tumor cells.
  • This application provides crystal structures obtained by co-crystal ization of pochoxime A and B with human HSP90a and a compound library extending the diversity of the pochoximes as well as asymmetric synthesis of the pochoxime analogs with C-6 modifications.
  • the present invention provides a compound of formula (I), or a harmaceutically acceptable salt, solvate, and/or prodrug thereof:
  • X is O, S or NR
  • Y is -OR, -0-(CH 2 ) m COOR, -0-(CH 2 ) m C0N(R) 2 , -N(R) 2 , -N(R)SOR or -N(R)S0 2 R, wherein the groups bound to the nitrogen atom may be in Z- or E- configuration;
  • Z 1 and Z 2 are independently hydrogen or -(CH 2 )-0-R z ;
  • R z is optionally substituted alkyl
  • R 1 and R 2 are independently hydrogen, halogen, OR, N(R) 2 , SR, azido, nitro, cyano, aliphatic, aryl, alkylaryl, arylalkyl, heterocyclyl, heteroaryl, -S(0)R, -S(0) 2 R, -S0 2 N(R) 2 , - N(R)S0 2 R, -N(CO)R, -N(CO)N(R) 2 , -N(CO)OR, -0(CO)R, -(CO)R, -(CO)OR, -(CO)N(R) 2 , - 0(CO)OR, or -0(CO)N(R) 2 ;
  • R 3 , R 4 , R 5 , R 6 , R 8 , R 9 and R 10 are independently hydrogen, halogen, azido, nitro, cyano, aliphatic, alkylaryl, aralkyl, aryl, heteroalkyl, alkylheteroaryl, heterocyclyl, heteroaryl, OR, N(R) 2 , SR, -0(C3 ⁇ 4) m N(R)C(0)(CH 2 ) p R, -0(CH 2 ) m OC(0)(CH 2 ) p R, -0(CH 2 ) m C(0)(CH 2 ) p N(R) 2 , -0(CH 2 ) m C(0)(CH 2 ) p OR, -0(CH 2 ) m N(R)C(0)(CH 2 ) p 0R, -0(CH 2 ) m N(R)C(0)(CH 2 )pN(R) 2 , -0(CH
  • each R is independently hydrogen, aliphatic, amino, azido, cyano, nitro, alkylamino, diaJkylamino, OH, alkoxy, carbonylamino, aminocarbonyl, alkoxycarbonyl, carbonyloxy, carboxy, acyl, aryl, alkaryl, arylalkyl including benzyl, heteroalkyl, heteroaryl, heterocyclyl, or a protecting group; or two R on the same nitrogen are taken together with the nitrogen to form a 5 to 8 membered heterocyclic or heteroaryl ring; wherein where a group contains more than one R substituent; wherein R is optionally substituted, and each R can be the same or different;
  • n and p are independently 0, 1, 2, 3, 4 or 5;
  • TM is a targeting moiety that specifically binds with a biological situs under
  • L-TM is a group an oxygen- or nitrogen-based functional group.
  • the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier.
  • the present invention provides a method of treating a patient with a disease comprising administering to the patient with the disease an effective amount of a compound of the present invention, wherein the disease is mediated by kinases and Heat Shock Protein 90 (HSP90).
  • the disease is an autoimmune disease, inflammatory disease, neurological or neurodegenerative disease, cancer, cardiovascular disease, allergy, asthma, or a hormone-related disease.
  • FIG. 1 Co-crystal structure of radicicol (panel A - pdb: lbgq) pochoxime A (panel B - pdb: 3inw) and pochoxime B (panel C - pdb: 3inx) with HSP90.
  • FIG. 1 Cellular efficacy of pochoximes A 1 B5C1D1 (IC50). Depletion of Her-2 in SkBr3 cells were treated with the inhibitor for 18h.
  • the present invention provides pochoxime derivatives as herein described.
  • the present compounds have structural formulae (I), (II), (Ilia), (Mb), and (IIIc) as well as any subgenus and species thereof, wherein a targeting moiety is appended to the allylic carbon 6 via a linkage moiety.
  • the allylic carbon 6 refers to the carbon atom (marked with *) covalently bonded to "L" as shown in structural formula (I) below:
  • the term "targeting moiety” can be a molecular moiety that specifically binds " with a biological situs under physiological conditions.
  • the targeting moiety may bind to a defined population of cells or selected cell type.
  • the targeting moiety may also bind a receptor, an oligonucleotide, an enzymatic substrate, an antigenic determinant, or other binding site present on or in the target cell or cell population.
  • the targeting moiety comprises an antibody, antibody fragment, or substance specific for a given receptor binding site.
  • the ligand, or targeting moiety comprises a receptor-specific peptide, carbohydrate, protein, lipid, nucleoside, peptide nucleic acid, or combinations thereof.
  • the ligand or targeting moiety is an organic compound.
  • the targeting moiety can be used to enhance the pharmacological properties or to specifically capitalize on an active transport mechanism to enrich the concentration of the drug in specific cell types using conjugates such as glucose or biotin or peptides known to interact with cell surface receptors.
  • the targeting group can be linked via an ether, ester, carbonate, thioether, thioester, amine, amide, urea, carbonate urea, thiourea, imine, hydrazine, hydrazone, and etc.
  • nitrogen -based functional group refers to an organic moiety containing a nitrogen and other atom(s) including any one or more of hydrogen, carbon, halegen, nitrogen, oxygen, sulfur, and etc., wherein the nitrogen atom is covalently attached to the allylic carbon 6.
  • nitrogen-based functional group include, but are not limited to, amino, azide, N-alkyl substituted amino, ⁇ , ⁇ -dialkyl substituted amino, acyl substituted amino, and etc. wherein each of the alkyl and acyl is optiontionally substituted.
  • nitrogen-based functional group refers to an organic moiety containing an oxygen and other atom(s) including any one or more of hydrogen, carbon, halegen, nitrogen, oxygen, sulfur, and etc., wherein the oxygen atom is covalently attached to the allylic carbon 6.
  • nitrogen-based functional group include, but are not limited to, hydroxyl, alkoxy, acyl substituted oxygen, and etc. wherein each of the alkyl and acyl is optiontionally substituted.
  • the present invention provides a compound of formula (I) as described above, or a pharmaceutically acceptable salt, solvate, and/or prodrug thereof.
  • the structural Formula (I) does not include the compound listed in Table X below:
  • X is O or NR.
  • Y is -OR, -0-(CH 2 ) m COOR or -0-(CH 2 ) m CON(R) 2.
  • R 1 and R 2 are independently hydrogen, halogen, or lower alkyl.
  • R 1 is hydrogen, halogen, or lower alkyl; and R 2 is hydrogen.
  • R z is lower alkyl, alkoxy-substituted lower alkyl, or aryl-substituted lower alkyl.
  • R z is methyl, ethyl, isopropyl, n- propyl, n-butyl, isobutyl, t-butyl, methoxy-ethyl, methoxy-methyl, chloromethyl, or benzyl.
  • L-TM is an oxygen or nitrogen-based functional group.
  • the compound in one embodiment, can be represented by structural formula (II):
  • X is O, S or NR
  • Y is -OR, -0-(CH 2 ) m COOR, -0-(CH 2 ) m CON(R) 2 , -N(R) 2 , -N(R)SOR or -N(R)S0 2 R, wherein the groups bound to the nitrogen atom may be in Z- or E- configuration;
  • Z 1 and Z 2 are independently hydrogen or -(CH 2 )-0-R z ;
  • R z is optionally substituted alkyl
  • R 1 and R 2 are independently hydrogen, halogen, or alkyl
  • R 3 , R 4 , R 5 , R 6 , R 8 , R 9 and R i0 are independently hydrogen, halogen, or alkyl
  • TM is a targeting moiety that specifically binds with a biological situs under physiological conditions; or alternatively, L-TM is a group an oxygen- or nitrogen-based functional group;
  • the compound in one embodiment, can be represented by structural Formula (Ilia).
  • Z 1 and Z 2 are -(CH 2 )-0-R z ;
  • R z is optionally substituted alkyl;
  • R 1 is H, halog or lower alkyl;
  • R 3 and R 9 are independently H or lower alkyl;
  • L-TM is an oxygen-based functional group.
  • the compound in one embodiment, can be represented by structural Formula (lllb :
  • Z 1 and Z 2 are -(CH2)-0-R z ;
  • R z is hydrogen or optionally substituted alkyl;
  • R 3 and R 9 are independently H or lower alkyl;
  • L-TM is a nitrogen-based functional group.
  • the compound in one embodiment, can be represented by structural Formula (IIIc):
  • Z 1 and Z 2 are -(CH 2 )-0-R z ;
  • R z is hydrogen or optionally substituted alkyl;
  • R 1 is H, halogen, or lower alkyl;
  • R 3 and R 9 are independently H or lower alkyl;
  • the present invention provides a compound selected from thyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethy
  • compound(s) of the present invention refers to compounds encompassed by structural formulae disclosed herein, e.g., Formula (I), (II), (Ilia), (Mb), and (IIIc), including any specific compounds within these formulae whose structure is disclosed herein.
  • Compounds may be identified either by their chemical structure and/or chemical name. When the chemical structure and chemical name conflict, the chemical structure is determinative of the identity of the compound.
  • the present compounds can inhibit the biological activity of a CK2 protein, and thereby is also referred to herein as an “inhibitor(s)" or "CK2 inhibitor(s)”.
  • a group may be substituted by one or more of a number of substituents
  • substitutions are selected so as to comply with principles of chemical bonding and to give compounds which are not inherently unstable and/or would be known to one of ordinary skill in the art as likely to be unstable under ambient conditions, such as aqueous, neutral, and several known physiological conditions.
  • a heterocycloalkyl or heteroaryl is attached to the remainder of the molecule via a ring heteroatom in compliance with principles of chemical bonding known to those skilled in the art thereby avoiding inherently unstable compounds.
  • Ci- alkyl Whenever a term in the specification is identified as a range (i.e. Ci- alkyl), the range independently refers to each element of the range.
  • C e alkyl means, independently, Ci, C 2 , C 3 , C 4 , Cs, or C 6 alkyl.
  • substituents when one or more substituents are referred to as being "independently selected from” a group, this means that each substituent can be any element of that group, and any combination of these groups can be separated from the group.
  • R 1 and R 2 can be independently selected from X, Y and Z, this separately includes the groups R 1 is X and R 2 is X; R 1 is X and R 2 is Y; R 1 is X and R 2 is Z; R 1 is Y and R 2 is X; R 1 is Y and R 2 is Y; R 1 is Y and R 2 is Z; R 1 is Z and R 2 is X; R 1 is Z and R 2 is Y; and R 1 is Z and R 2 is Z.
  • aliphatic as used herein means straight-chain, branched or cyclic typically of C) to Ci8, and in certain embodiment of Ci to Cio or of d to Ce, hydrocarbons which are completely saturated or which contain one or more units of unsaturation but which are not aromatic.
  • suitable aliphatic groups include substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
  • alkyl used alone or as part of a larger moiety includes both straight and branched chains containing one to twelve carbon atoms.
  • alkenyl and “alkynyl” used alone or as part of a larger moiety shall include both straight and branched chains containing two to twelve carbon atoms.
  • cycloalkyl used alone or as part of a larger moiety shall include cyclic C 3 -C
  • Aliphatic groups can be optionally substituted with one or more moieties, including but not limited to, alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, thiol, imine, sulfonic acid, sulfate, sulfonyl, sulfanyl, sulfinyl, sulfamoyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphate, phosphonate, or any other viable functional group that does not inhibit the pharmacological activity of this compound,
  • alkyl refers to a saturated straight, branched, or cyclic, primary, secondary, or tertiary hydrocarbon, including but not limited to groups typically of C ⁇ to CM and in certain embodiment of Ci to Cio or of C ⁇ to C 6 , and specifically includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, cyclopentyl, isopentyl, neopentyl, hexylisohexyl, cyclohexyl, cyclohexylmethyl, 3- methylpentyl, 2, 2- dimethylbutyl and 2,3-dimethylbutyl. Alkyl groups may be substituted as noted above for the term "aliphatic.”
  • lower alkyl refers to optionally substituted Ci to Ce saturated straight, branched, or if appropriate, a cyclic (for example, cyclopropyl) alkyl group, including both substituted and unsubstituted forms.
  • alkyl groups are methyl, ethyl, propyl, wopropyl, cyclopropyl, butyl, secbutyl, isobutyl, tertb y ⁇ , cyclobutyl, 1-methylbutyl, 1 , 1 -dimethylpropyl, pentyl, cyclopentyl, isopentyl, neopentyl, cyclopentyl, hexyl, isohexyl, and cyclohexyl.
  • the alkyl group can be unsubstituted or substituted with one or more moieties selected from the group consisting of alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, thiol, imine, sulfonic acid, sulfate, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrazine, carbamate, phosphonic acid, phosphate, phosphonate, or any other viable functional group that does not
  • halo or halogen, as used herein, includes chloro, bromo, iodo, and fluoro.
  • chiral as used herein includes a compound that has the property that it is not superimposable on its mirror image.
  • tautomer refers to alternate structures which are recognized in the art to be in equilibrium with the depicted structure.
  • the enol structure below is a tautomer of the ketone structure and recognized to be in equilibrium with the ketone structure.
  • solvate or “pharmaceutically acceptable solvate,” is a solvate formed from the association of one or more solvent molecules to one or more molecules of a compound of any one of formulas I, ⁇ , II, ⁇ , III, ⁇ , IV or V or the compounds depicted in Table 1.
  • solvate includes hydrates (e.g., hemi-hydrate, mono-hydrate, dihydrate, trihydrate, tetrahydrate, and the like).
  • alkylthio refers to a straight or branched chain alkylsulfide of the number of carbons specified, such as for example, ethylthio, -S-alkyl, -S-alkenyl, -S- alkynyl, etc.
  • alkylamino or arylamino refer to an amino group that has one or two alkyl or aryl substituents, respectively. Unless otherwise specifically stated in this
  • alkyl when alkyl is a suitable moiety, then it is a lower alkyl, whether substituted or unsubstituted.
  • alkylsulfonyl means a straight or branched alkylsulfone of the number of carbon atoms specified, as for example, Ci_ alkylsulfonyl or methylsulfonyl.
  • alkoxycarbonyl refers to a straight or branched chain ester of a carboxylic acid derivative of the number of carbon atoms specified, such as for example, a
  • nitro means -N0 2 ; the term “sulfhydryl” means -SH; and the term “sulfonyl” means -SO2.
  • alkenyl and alkynyl refer to alkyl moieties, including both substituted and unsubstituted forms wherein at least one saturated C-C bond is replaced by a double or triple bond.
  • C 2 .6 alkenyl may be vinyl, allyl, 1 -propenyl, 2-propenyl, 1-butenyl, 2- butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3- hexenyl, 4-hexenyl, or 5-hexenyl.
  • C 2- 6 alkynyl may be ethynyl, 1 -propynyl, 2- propynyl, 1 -butynyl, 2-butynyl, 3-butynyl, 1 -pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1 - hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, or 5-hexynyl.
  • alkylene includes a saturated, straight chain, divalent alkyl radical of the formula -(CH 2 ) n -, wherein "n" may be any whole integer from 1 to 12.
  • Alkyl alkoxy
  • reference to an individual radical such as “propyl” embraces only that straight-chain radical, whereas a branched chain isomer such as “isopropyl” is specifically termed such.
  • aryl refers to any stable monocyclic, bicyclic, or tricyclic carbon ring of up to 8 members in each ring, wherein at least one ring is aromatic as defined by the Huckel 4n+2 rule, and especially phenyl, biphenyl, or naphthyl.
  • the term includes both substituted and unsubstituted moieties.
  • the aryl group can be optionally substituted with one or more moieties.
  • substituents include alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfate, sulfonyl, sulfanyl, sulfinyl, sulfamoyl, ester, carboxylic acid, amide, phosphate, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrazine, carbamate, phosphonic acid, phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, et ah, "
  • alkaryl or “alkylaryl” refers to an alkyl group with an aryl substituent or an alkyl group linked to the molecule through an aryl group as defined herein.
  • aralkyl or “arylalkyl” refers to an aryl group substituted with an alkyl substituent or linked to the molecule through an alkyl group as defined above.
  • alkoxy means a straight or branched chain alkyl group having an attached oxygen radical, the alkyl group having the number of carbons specified or any number within this range.
  • acyl includes a group of the formula C(0)R', wherein R' is an straight, branched, or cyclic alkyl (including lower alkyl), carboxylate residue of an amino acid, aryl including phenyl, heteroaryl, alkaryl, aralkyl including benzyl, alkoxyalkyl including methoxymethyl, aryloxyalkyl such as phenoxymethyl; or substituted alkyl (including lower alkyl), aryl including phenyl optionally substituted with chloro, bromo, fluoro, iodo, Ci to C4 alkyl or Ci to C4 alkoxy, sulfonate esters such as alkyl or aralkyl sulphonyl including methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxy-trityl, substituted benzyl, alkatyl, aralkyl including benzyl, alkoxy
  • Aryl groups optimally comprise a phenyl group.
  • acyl groups include acetyl, trifluoroacetyl, methylacetyl, cyclopropylacetyl, cyclopropyl- carboxy, propionyl, butyryl, isobutyryl, hexanoyl, heptanoyloctanoyl, neo- heptanoyl, phenylacetyl, 2-acetoxy-2-phenylacetyl, diphenylacetyl, a-methoxy-a- trifluoromethyl-phenylacetyl, bromoacetyl, 2-nitro-benzeneacetyl, 4-chloro-benzeneacetyl, 2- chloro-2,2-diphenylacetyl, 2-chloro-2-phenylacetyl, trimethylacetyl, chlorodifluoroacetyl, perfluoroacetyl,
  • cyclobutane-carboxyl perfluorocyclohexyl carboxyl, 4-methylbenzoyl, chloromethyl isoxazolyl carbonyl, perfluorocyclohexyl carboxyl, crotonyl, l-methyl-lH-indazole-3- carbonyl, 2-propenyl, isovaleryl, 1 -pyrrolidinecarbonyl, 4-phenylbenzoyl.
  • Aryl groups optimally comprise a phenyl group.
  • heteroatom includes an atom other than carbon or hydrogen in the structure of a heterocyclic compound, nonlimiting examples of which are nitrogen, oxygen, sulfur, phosphorus or boron.
  • heterocycle includes non- aromatic ring systems having four to fourteen members, preferably five to ten, in which one or more ring carbons, preferably one to four, are each replaced by a heteroatom.
  • heterocyclic rings examples include 3-lH-benzimidazol-2-one, (l-substituted)-2-oxo-benzimidazol-3-yl, 2- tetrahydro-furanyl, 3-tetrahydrofuranyl, 2-tetrahydropyranyl, 3-tetrahydropyranyl, 4-tetra- hydropyranyl, [l,3]-dioxalanyl, [l ,3]-dithiolanyl, [l ,3]-dioxanyl, 2-tetra-hydro-thiophenyl, 3- tetrahydrothiophenyl, 2-morpholinyl, 3-morpholinyl, 4-morpholinyl, 2-thiomorpholinyl, 3- thiomorpholinyl, 4-thiomorpholinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-piperazinyl, 2-piperazinyl, 1 -piperidiny
  • heterocyclyl or “heterocyclic”, as it is used herein, is a group in which a non- aromatic heteroatom-containing ring is fused to one or more aromatic or non-aromatic rings, such as in an indolinyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment is on the non-aromatic heteroatom-containing ring.
  • heterocycle “heterocyclyl”, or “heterocyclic” whether saturated or partially unsaturated, also refers to rings that are optionally substituted.
  • heteroaryl used alone or as part of a larger moiety as in “heteroaralkyl” or “heteroarylalkoxy”, refers to heteroaromatic ring groups having five to fourteen members.
  • heteroaryl rings examples include 2-furanyl, 3-furanyl, 3-furazanyI, N-imidazolyl, 2- imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2- oxadiazolyl, 5-oxadiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 1-pyrrolyl, 2-pyrrolyl, 3- pyrrolyl, 1-pyrazolyl, 2-pyrazolyl, 3-pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 3-pyridazinyl, 2-thiazoIyl, 4-thiazoIyI, 5-thiazoIyl, 5-tetrazolyi, 2- triazolyl, 5-triazolyl, 2-thienyl, 3-thienyl
  • heteroaryl is a group in which a heteroatomic ring is fused to one or more aromatic or nonaromatic rings where the radical or point of attachment is on the heteroaromatic ring. Examples include tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido [3,4-d]pyrimidinyl.
  • heteroaryl also refers to rings that are optionally substituted.
  • heteroaryl may be used interchangeably with the term “heteroaryl ring” or the term “heteroaromatic”.
  • amino as used herein unless otherwise specified, includes a moiety represented by the structure "-N(R) 2 ", and includes primary, secondary and tertiary amines optionally substituted by alkyl, aryl, heterocyclyl, and/or sulfonyl groups.
  • R>2 may represent two hydrogen atoms, two alkyl moieties, or one hydrogen and one alkyl moiety.
  • Counterion refers to a negatively or positively charged ionic species that accompanies an oppositely charged ionic species in order to maintain electric neutrality.
  • Negatively charged counterions include inorganic counten ' ons and organic counterions, including but not limited to, chloro, bromo, iodo, fluoro, phosphate, acetate, formate, sulfonate, trifluoroacetate acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobro
  • Positively charged counterions include, but are not limited to, alkali metal (e.g., sodium and potassium), alkaline earth metal (e.g., magnesium), ammonium and N + (Ci.4 alkyl) 4 counterions.
  • alkali metal e.g., sodium and potassium
  • alkaline earth metal e.g., magnesium
  • ammonium and N + (Ci.4 alkyl) 4 counterions include, but are not limited to, alkali metal (e.g., sodium and potassium), alkaline earth metal (e.g., magnesium), ammonium and N + (Ci.4 alkyl) 4 counterions.
  • the term "quaternary amine” as used herein includes quaternary ammonium salts that have a positively charged nitrogen. They are formed by the reaction between a basic nitrogen in the compound of interest and an appropriate quaternizing agent such as, for example, methyliodide or benzyliodide.
  • substituted includes multiple degrees of substitution by one or more named substituents such as, for example, halo, hydroxyl, thio, alkyl, alkenyl, alkynyl, nitro, cyano, azido, amino, carboxamido, etc.
  • substituents such as, for example, halo, hydroxyl, thio, alkyl, alkenyl, alkynyl, nitro, cyano, azido, amino, carboxamido, etc.
  • substituents such as, for example, halo, hydroxyl, thio, alkyl, alkenyl, alkynyl, nitro, cyano, azido, amino, carboxamido, etc.
  • protected refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction or for other purposes.
  • oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis.
  • protecting group refers to a group that may be attached to a reactive group, including heteroatoms such as oxygen or nitrogen, to prevent the reactive group from participating in a reaction. Any protecting groups taught in for example, in Greene et al., Protective Groups in Organic Synthesis. John Wiley & Sons, 3 rd Ed., 1999, may be used.
  • suitable protecting groups include but are not limited to alkoxyalkyl groups such as ethoxymethyl and methoxymethyl; silyl protecting groups, such tert-butyldimethyl silyl (TBS), phenyldimethylsilyl, trimethylsilyl (TMS), 2-trimethylsilylethoxymethyl (SE ) and 2- trimethylsilylethyl; and benzyl and substituted benzyl.
  • alkoxyalkyl groups such as ethoxymethyl and methoxymethyl
  • silyl protecting groups such tert-butyldimethyl silyl (TBS), phenyldimethylsilyl, trimethylsilyl (TMS), 2-trimethylsilylethoxymethyl (SE ) and 2- trimethylsilylethyl
  • TBS tert-butyldimethyl silyl
  • TMS phenyldimethylsilyl
  • TMS trimethylsilyl
  • SE 2-trimethylsilylethoxymethyl
  • patient includes human and veterinary subjects.
  • an “effective amount” is the quantity of compound in which a beneficial outcome is achieved when the compound is administered to a patient or alternatively, the quantity of compound that possesses a desired activity in vivo or in vitro.
  • a beneficial clinical outcome includes reduction in the extent or severity of the symptoms associated with the disease or disorder and/or an increase in the longevity and/or quality of life of the patient compared with the absence of the treatment.
  • a "beneficial clinical outcome” includes a reduction in tumor mass, a reduction in the rate of tumor growth, a reduction in metastasis, a reduction in the severity of the symptoms associated with the cancer and/or an increase in the longevity of the subject compared with the absence of the treatment.
  • the precise amount of compound administered to a subject will depend on the type and severity of the disease or condition and on the characteristics of the patient, such as general health, age, sex, body weight and tolerance to drugs, it will also depend on the degree, severity and type of proliferative disorder. The skilled artisan will be able to determine appropriate dosages depending on these and other factors.
  • kinase-inhibiting amount refers to an amount of the compound that inhibits a kinase enzyme compared to a control as tested by the methods described herein.
  • HSP 90-inhibiting amount refers to an amount of the compound that inhibits HSP90 compared to a control as tested by the methods described herein.
  • biological sample includes, without limitation, cell cultures or extracts thereof; preparations of an en2yme suitable for in vitro assay; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
  • cancer includes, but is not limited to, solid tumors and blood borne tumors and include, but is not limited to, the following cancers: breast, ovary, cervix, prostate, testis, genitourinary tract, esophagus, larynx, glioblastoma, stomach, skin, keratoacanthoma, lung, epidermoid carcinoma, large cell carcinoma, small cell carcinoma, lung adenocarcinoma, bone, colon, adenoma, pancreas, adenocarcinoma, thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder carcinoma, liver carcinoma and biliary passages, kidney carcinoma, myeloid disorders, lymphoid disorders, Hodgkin's, hairy cells, buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx, small intestine, colon-rectum, large intestin
  • cancer includes primary cancer, cancers secondary to treatment, and metastatic cancers.
  • pharmaceutically acceptable carrier refers to a non-toxic carrier, adjuvant, or vehicle that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof.
  • Excipient refers to a diluent, adjuvant, vehicle, or carrier with which a compound is administered.
  • HSP90-mediated disease or "HSP90-mediated condition” refers to a condition in which HSP90 is known to pay a role.
  • the conditions include but are not limited to inflammatory disorders, abnormal cellular proliferation, autoimmune disorders, ischemia, fibrogenetic disorders including but not limited to scleroderma, polymyositis, systemic lupus, rheumatoid arthritis, liver cirrhosis, keloid formation, interstitial nephritis, and pulmonary fibrosis. (Strehlovv, WO 02/02123; PCT/US01/20578).
  • pharmaceutically acceptable salt and “prodrug” are used throughout the specification to describe any pharmaceutically acceptable form (such as a salt, an ester, a phosphate ester, salt of an ester or a related group) of a compound which, upon administration to a patient, provides the compound described in the specification. In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compounds as salts may be appropriate.
  • pharmaceutically acceptable salts or complexes refers to salts or complexes that retain the desired biological activity of the compounds of the present invention and exhibit minimal undesired toxicological effects.
  • Non-limiting examples of such salts are (a) acid addition salts formed with inorganic acids such as sulfate, nitrate, hydrochloric, phosphate, and the like.
  • inorganic acids such as sulfate, nitrate, hydrochloric, phosphate, and the like.
  • salts formed by the addition of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like are examples of salts formed with inorganic acids such as sulfate, nitrate, hydrochloric, phosphate, and the like.
  • salts formed with organic acids are encompassed by the invention, including tosylate, methanesulfonate, acetate, citrate, malonate, tartrate, succinate, benzoate, ascorbate, a-ketoglutarate, and a-glycerophosphate salts, such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and polygalcturonic acid.
  • the invention also encompasses (b) base addition salts, including formed with metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, sodium, potassium, lithium and the like, or with a cation formed from ammonia, N,N- dibenzylethylenediamine, D-glucosamine, tetraethylammonium, or ethylenediamine; or (c) combinations of (a) and (b); e.g., a zinc tannate salt or the like.
  • metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, sodium, potassium, lithium and the like
  • a cation formed from ammonia, N,N- dibenzylethylenediamine, D-glucosamine, tetraethylammonium, or ethylenediamine or combinations of (a) and (b); e.g.
  • quaternary salts known by those skilled in the art, which specifically include the quaternary ammonium salt of the formula -NR + A " , wherein R is as defined above and A is a counterion, including chloride, bromide, iodide, -O-alkyl,
  • toluenesulfonate methylsulfonate, sulfonate, phosphate, or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, citrate, tartrate, ascorbate, benzoate, cinnamoate, mandeloate, benzyloate, and diphenylacetate.
  • carboxylate such as benzoate, succinate, acetate, glycolate, maleate, malate, citrate, tartrate, ascorbate, benzoate, cinnamoate, mandeloate, benzyloate, and diphenylacetate.
  • compositions may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
  • prodrugs refer to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form the compound of the present invention.
  • Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound.
  • Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, dephosphorylated to produce the active compound.
  • a suitable prodrug may be an ester or an amide of a carboxylic acid that is hydrolyzed to form the acid.
  • Non-limiting examples of prodrugs include but are not limited to alkyl or aralkyl esters or amides, including methyl, ethyl, propyl, benzyl and substituted benzyl esters or amides. Prodrugs also comprise phosphate esters of the compounds.
  • Compounds of the present invention having a chiral center may exist in and be isolated in optically active and racemic forms.
  • the present invention encompasses any racemic, optically- active, diastereomeric, polymorphic, or stereo isomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein.
  • the compounds are prepared in optically active form by asymmetric synthesis using the processes described herein or synthetic transformations known to those skilled in the art.
  • optically active materials include at least the following. i) physical separation of crystals--a technique whereby macroscopic crystals of the individual enantiomers are manually separated. This technique can be used if crystals of the separate enantiomers exist, i.e., the material is a conglomerate, and the crystals are visually distinct;
  • simultaneous crystallization a technique whereby the individual enantiomers are separately crystallized from a solution of the racemate, possible only if the latter is a conglomerate in the solid state;
  • enzymatic resolutions a technique whereby partial or complete separation of a racemate by virtue of differing rates of reaction for the enantiomers with an enzyme
  • enzymatic asymmetric synthesis a synthetic technique whereby at least one step of the synthesis uses an enzymatic reaction to obtain an enatiomerical!y pure or enriched synthetic precursor of the desired enantiomer;
  • first- and second-order asymmetric transformations a technique whereby diastereomers from the racemate equilibrate to yield preponderance in solution of the diastereomer from the desired enantiomer or where preferential crystallization of the diastereomer from the desired enantiomer perturbs the equilibrium such that eventually in principle all the material is converted to the crystalline diastereomer from the desired enantiomer. The desired enantiomer is then released from the diastereomer;
  • kinetic resolutions this technique refers to the achievement of partial or complete resolution of a racemate (or of a further resolution of a partially resolved compound) by virtue of unequal reaction rates of the enantiomers with a chiral, non-racemic reagent or catalyst under kinetic conditions;
  • enantiospecific synthesis from non-racemic precursors a synthetic technique whereby the desired enantiomer is obtained from non-chiral starting materials and where the stereochemical integrity is not or is only minimally compromised over the course of the synthesis;
  • the stationary phase can be made of chiral material or the mobile phase can contain an additional chiral material to provoke the differing interactions;
  • xiii) transport across chiral membranes a technique whereby a racemate is placed in contact with a thin membrane barrier.
  • the barrier typically separates two miscible fluids, one containing the racemate, and a driving force such as concentration or pressure differential causes preferential transport across the membrane barrier. Separation occurs as a result of the non- racemic chiral nature of the membrane which allows only one enantiomer of the racemate to pass through.
  • the present invention provides pharmaceutical compositions (i.e., formulations).
  • the pharmaceutical compositions can comprise a compound of the present invention, as described herein, which is admixed with at least one pharmaceutically acceptable excipient or carrier. Frequently, the composition comprises at least two pharmaceutically acceptable excipients or carriers.
  • compositions and methods of the present invention will typically be used in therapy for human patients, they may also be used in veterinary medicine to treat similar or identical diseases.
  • the compositions may, for example, be used to treat mammals, including, but not limited to, primates and domesticated mammals.
  • the compositions may, for example be used to treat herbivores.
  • the compositions of the present invention include geometric and optical isomers of one or more of the drugs, wherein each drug is a racemic mixture of isomers or one or more purified isomers.
  • compositions suitable for use in the present invention include
  • compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
  • Any suitable formulation of a compound described above can be prepared for administration.
  • Any suitable route of administration may be used, including, but not limited to, oral, parenteral, intravenous, intramuscular, transdermal, topical, subcutaneous routes, and inhalation.
  • Preparation of suitable formulations for each route of administration are known in the art. A summary of such formulation methods and techniques is found in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co., Easton, PA, which is incorporated herein by reference. Other examples of drug formulations can be found in Liberman, H. A.
  • each substance or of the combination of two substances will generally include a diluent as well as, in some cases, adjuvants, buffers, preservatives and the like.
  • the substances to be administered can be administered also in liposomal compositions or as microemulsions.
  • formulations can be prepared in conventional forms as liquid solutions or suspensions or as solid forms suitable for solution or suspension in liquid prior to injection or as emulsions.
  • Suitable excipients include, for example, water, saline, dextrose, glycerol and the like.
  • Such compositions may also contain amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as, for example, sodium acetate, sorbitan monolaurate, and so forth.
  • Systemic administration may also include relatively noninvasive methods such as the use of suppositories, transdermal patches, transmucosal delivery and intranasal administration.
  • Oral administration is also suitable for compounds of the invention. Suitable forms include syrups, capsules, tablets, as is understood in the art.
  • an effective dose can be readily determined by the use of conventional techniques and by observing results obtained under analogous circumstances.
  • determining the effective dose a number of factors are considered including, but not limited to: the species of patient; its size, age, and general health; the specific disease involved; the degree of involvement or the severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; and the use of concomitant medication.
  • the appropriate dosage of the a compound described above often is 0.01 to 1500 mg/kg, and sometimes 0.1 to 10 mg/kg. Dosage levels are dependent on the nature of the condition, drug efficacy, the condition of the patient, the judgment of the practitioner, and the frequency and mode of administration; however, optimization of such parameters is within the ordinary level of skill in the art.
  • Typical systemic dosages for all of the herein described conditions are those ranging from 0.01 mg/kg to 1500 mg/kg of body weight per day as a single daily dose or divided daily doses.
  • Preferred dosages for the described conditions range from 0.5 to 1500 mg per day.
  • a more particularly preferred dosage for the desired conditions ranges from 5 to 750 mg per day.
  • Typical dosages can also range from 0.01 to 1500, 0.02 to 1000, 0.2 to 500, 0.02 to 200, 0.05 to 100, 0.05 to 50, 0.075 to 50, 0.1 to 50, 0.5 to 50, 1 to 50, 2 to 50, 5 to 50, 10 to 50, 25 to 50, 25 to 75, 25 to 100, 100 to 150, or 150 or more mg/kg/day, as a single daily dose or divided daily doses.
  • the compounds are given in doses of between about 1 to about 5, about 5 to about 10, about 10 to about 25 or about 25 to about 50 mg/kg.
  • Typical dosages for topical application are those ranging from 0.001 to 100%
  • the compounds are conveniently administered in units of any suitable dosage form, including but not limited to one containing from about 7 to 3000 mg, from about 70 to 1400 mg, or from about 25 to 1000 mg of active ingredient per unit dosage form.
  • an oral dosage of from about 50 to 1000 mg is usually convenient, including in one or multiple dosage forms of 50, 100, 200, 250, 300, 400, 500, 600, 700, 800, 900 or 1000 mgs.
  • Lower dosages may be preferable, for example, from about 10 to 100 or 1 to 50 mgs.
  • lower doses may be utilized in the case of administration by a non-orai route, as for example, by injection or inhalation.
  • the compound is administered for a sufficient time period to alleviate the undesired symptoms and the clinical signs associated with the condition being treated.
  • the active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutic amount of compound in vivo in the absence of serious toxic effects.
  • Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions are generally known in the art.
  • ion exchangers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, solvents, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, silicates, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, oils, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
  • buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, solvents, salts
  • Pharmaceutically accepted vehicles can contain mixtures of more than one excipient in which the components and the ratios can be selected to optimize desired characteristics of the formulation including but not limited to shelf-life, stability, drug load, site of delivery, dissolution rate, self- emulsification, control of release rate and site of release, and metabolism.
  • Formulations can be prepared by a variety of techniques known in the art. Examples of formulation techniques can be found in literature publications and in texts such as "Water- insoluble drug formulation", edited by Rong Liu, 2000, Interpharm Press.
  • the concentration of active compound in the drug composition will depend on absorption, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
  • the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
  • the compounds described herein are particularly useful for the treatment or prevention of a disorder mediated by kinases or mediated by HSP90.
  • the compounds described herein are useful for the treatment or prevention of a proliferative disorder, including cancer metastasis.
  • the compounds described herein are useful for the treatment or prevention of an inflammatory or autoimmune disorder associated by kinases or HSP90.
  • An aspect of the invention relates to compounds and compositions that are useful for treating cancer.
  • Another aspect of the invention relates to the treatment of the following cancers: breast, ovary, cervix, prostate, testis, genitourinary tract, esophagus, larynx, glioblastoma, stomach, skin, keratoacanthoma, lung, epidermoid carcinoma, large cell carcinoma, small cell carcinoma, lung adenocarcinoma, bone, colon, adenoma, pancreas, adenocarcinoma, thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder carcinoma, liver carcinoma and biliary passages, kidney carcinoma, myeloid disorders, lymphoid disorders, Hodgkin's, hairy cells, buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx, small intestine, colon-rectum, large intestine, rectum, brain and central nervous system, and leukemia.
  • Another aspect of the invention is a method for treating cancer comprising administering an effective amount of a compound of the present invention to a patient with cancer.
  • Angiogenesis is characterized by the proliferation of endothelial cells to form new blood vessels (often called neovascularization). Inhibition of mitosis of endothelial cells results in inhibition of angiogenesis. Another aspect of this invention therefore relates to inhibition of undesirable mitosis, including undesirable angiogenesis.
  • a mammalian disease characterized by undesirable cell mitosis includes, but is not limited to, excessive or abnormal stimulation of endothelial cells (e.g., atherosclerosis), solid tumors and tumor metastasis, benign tumors, for example, hemangiomas, trachomas, and pyogenic granulomas, vascular malfunctions, abnormal wound healing, inflammatory and immune disorders, Bechet's disease, gout or gouty arthritis, abnormal angiogenesis accompanying rheumatoid arthritis, skin diseases, such as psoriasis, diabetic retinopathy and other ocular angiogenic diseases such as retinopathy of prematurity (retrolental fibroplasic), macular degeneration, corneal graft rejection, neovascular glaucoma and Osier Weber syndrome (Osler-Weber-Rendu disease).
  • endothelial cells e.g., atherosclerosis
  • solid tumors and tumor metastasis
  • compositions described above can be used as a birth control agent by reducing or preventing uterine vascularization required for embryo implantation. Accordingly, the compositions described above can be used to block ovulation and implantation of a blastula or to block menstruation (induce amenorrhea).
  • Diseases associated with undesirable mitosis including neovascularization can be treated according to the present invention.
  • diseases include, but are not limited to, ocular neovascular disease, diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma and retrolental fibroplasias, epidemic keratoconjunctivitis, Vitamin A deficiency, contact lens overwear, atopic keratitis, superior limbic keratitis, pterygium keratitis sicca, Sjogren's syndrome, acne rosacea, phylectenulosis, syphilis, Mycobacteria infections, lipid degeneration, chemical bums, bacterial ulcers, fungal ulcers, Herpes simplex infections, Herpes zoster infections, protozoan infections, Kaposi's sarcoma, Mooren's ulcer, Terrien's marginal degeneration, marginal keratolysis
  • diseases associated with undesirable mitosis including neovascularization can be treated according to the present invention.
  • diseases include, but are not limited to, sickle cell anemia, sarcoid, pseudoxanthoma elasticum, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis, Lyme's disease, systemic lupus erythematosis, Eales' disease, Bechet's disease, infections causing a retinitis or choroiditis, presumed ocular histoplasmosis, Best's disease, myopia, optic pits, Stargart's disease, pars planitis, chronic retinal detachment, hyperviscosity syndromes, toxoplasmosis, and post-laser complications.
  • diseases include, but are not limited to, diseases associated with rubeosis (neovascularization of the iris and the angle) and diseases caused by the abnormal proliferation of fibrovascular or fibrous tissue including all forms of proliferative vitreoretinopathy, whether or not associated with diabetes.
  • Another aspect of the invention relates to the treatment of inflammatory diseases including, but no limited to, excessive or abnormal stimulation of endothelial cells (e.g. , atherosclerosis), solid tumors and tumor metastasis, benign tumors, for example, hemangiomas, acoustic neuromas, trachomas, and pyogenic granulomas, vascular malfunctions, abnormal wound healing, inflammatory and immune disorders, Bechet's disease, gout or gouty arthritis, abnormal angiogenesis accompanying rheumatoid arthritis, skin diseases, such as psoriasis, diabetic retinopathy and other ocular angiogenic diseases such as retinopathy of prematurity (retrolental fibroplasic), macular degeneration, corneal graft rejection, neovascular glaucoma and Osier Weber syndrome (Osier- Weber-Rendu disease).
  • endothelial cells e.g. , atherosclerosis
  • compositions described above can be used to block ovulation and implantation of a blastula or to block menstruation (induce amenorrhea).
  • Another aspect of this invention relates to a method of inhibiting HSP90 activity in a patient, comprising administering to a patient an effective amount of a compound of the present invention or a pharmaceutically acceptable salt or prodrug thereof.
  • the invention also provides a method for treating a disease that is mediated by HSP90.
  • Another aspect of this invention relates to a method of inhibiting Aurora A activity in a patient, comprising administering to a patient an effective amount of a compound of the present invention or a pharmaceutically acceptable salt or prodrug thereof.
  • Another aspect of this invention relates to a method of treating or preventing a GSK-3- mediated disease with a GSK-3 inhibitor, comprising administering to a patient an effective amount of a compound of the present invention or a pharmaceutically acceptable salt or prodrug thereof.
  • Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient comprising administering to the patient a compound of the present invention or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a CDK-2- mediated disease comprising administering to a patient in need of such a treatment a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
  • Another aspect of the invention relates to inhibiting CDK-2 activity in a biological sample or a patient, which method comprises administering to the patient a compound of the present invention, or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing an ERK-2- mediated diseases comprising administering to a patient in need of such a treatment a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
  • Another aspect of the invention relates to inhibiting E K-2 activity in a biological sample or a patient, which method comprises administering to the patient a compound of the present invention, or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing an AKT- mediated diseases comprising administering to a patient in need of such a treatment a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
  • Another aspect of the invention relates to inhibiting AKT activity in a biological sample or a patient, which method comprises administering to the patient a compound of the present invention, or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a Src- mediated disease comprising administering to a patient in need of such a treatment a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.
  • Another aspect of the invention relates to inhibiting Src activity in a biological sample or a patient, which method comprises administering to the patient a compound of the present invention, or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing an Lck- mediated disease with an Lck inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of the present invention, or a pharmaceutical composition thereof.
  • Another aspect of the invention relates to inhibiting Lck activity in a biological sample or a patient, which method comprises administering to the patient a compound of the present invention, or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing an Abl- mediated disease with an Abl inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of the present invention, or a pharmaceutical composition thereof.
  • Another aspect of the invention relates to inhibiting Abl activity in a biological sample or a patient, which method comprises administering to the patient a compound of the present invention, or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a cKit- mediated disease comprising administering to a patient in need of such a treatment a
  • Another aspect of the invention relates to inhibiting cKit activity in a biological sample or a patient, which method comprises administering to the patient a compound of the present invention, or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a Flt3- mediated disease comprising administering to a patient in need of such a treatment a
  • Another aspect of the invention relates to inhibiting Flt3 activity in a biological sample or a patient, which method comprises administering to the patient a compound of the present invention, or a composition comprising said compound.
  • Another aspect of this invention relates to a method of treating or preventing a DR- mediated disease comprising administering to a patient in need of such a treatment a therapeutically effective amount of a compound of the present invention, or a pharmaceutical composition thereof.
  • Another aspect of the invention relates to inhibiting KDR activity in a biological sample or a patient, which method comprises administering to the patient a compound of the present invention, or a composition comprising said compound.
  • An amount effective to inhibit protein kinase is an amount that causes measurable inhibition of the kinase activity when compared to the activity of the enzyme in the absence of an inhibitor. Any method may be used to determine inhibition, such as, for example, the Biological Testing Examples described below.
  • Preparation of the present compounds may include one or more steps of protection and deprotection (e.g., the formation and removal of acetal groups).
  • Guidance for selecting suitable protecting groups can be found, for example, in Greene & Wuts, "Protective Groups in Organic Synthesis," Wiley Interscience, 1999.
  • the preparation may include various purifications, such as column chromatography, flash chromatography, thin-layer chromatography (TLC), recrystallization, distillation, high-pressure liquid chromatography (HPLC) and the like.
  • the synthetic planning of the library was based on previously developed chemistry 1271 and leveraged on the use of solid phase synthesis and polymer-bound reagents.
  • a library with four points of diversity was envisioned (see 1, Scheme 2) which would stem from a divergent coupling of fragment A to B followed by oxime formation and introduction of fragment C and then D.
  • the choice of fragments A to D was based on preliminary structure-activity data of the present inventors' 27"291 and the objective of biasing the conformational profile of the macrocycle through different ring sizes and additional small substituents.
  • Scheme 2 Synthetic planning of the library and structure of the library fragments.
  • the same product could be obtained by conjugate reduction of the coupling product obtained with fragment Bl using aCNBH3 (25-50%).
  • Each product was treated with aminooxyacetic acid and, after filtration through a pad of silica to remove excess aminooxyacetic acid, the resulting oximes 2 were loaded on a chlorotrityl resin to afford polymer-bound intermediates 3.
  • a high loading resin (1.1 mmol/g) was used in excess and once all starting material had been consumed (24 h), the resin was capped with the addition of AcOH to afford ten resins of 3.
  • the 2-(trimethylsilyl)ethyl ester was then cleaved under the action of TBAF to afford 4 and each batch of resin was further divided in eight batches for the esterification or amide formation with fragments C. It was found to be essential to thoroughly wash the resin with a 1% AcOH solution in CH2CI2 after the TBAF deprotection to protonate the polymer-bound carboxylate and remove tetrabutyl ammonium salts. Each resin was then subjected to a metathesis reaction with the second generation Grubbs catalyst 1331 under microwave irradiation until 120 °C for 45 min to afford the desired polymer- bound macrocycles 5. To ensure completion of the reaction and equilibration to the
  • the macrocycles bearing a free carboxylic acid were then further divided in separate pools for coupling to fragments D using polymer-bound carbodiimide and 4- DMAP with an excess of amine (>2.0 equiv) which afforded the products with excellent conversion (>90%).
  • the excess of amine was removed during the evaporation or sequestered along with DMAP during the subsequent treatment with a large excess (10 equiv) of sulfonic acid resin in MeOH to perform the EOM deprotection (>75% isolated yield for two steps).
  • Reagents and conditions a) LDA (2.0 equiv), B (0.9 equiv), THF, - 78 °C, 20 min, 50-85%; b) H 2 NOCH 2 C0 2 H (5.0 equiv), 40 °C, py, 24-48h, 85-95%; c) PS-ClTr-Cl (3.0 equiv), Et/Pr 2 N (6.0 equiv), CH 2 C1 2 , 23 °C, 24 h; then AcOH (20 equiv), 23 °C, 24 h; d) TBAF (4.0 equiv), 23 °C 4 h; e) C (5.0 equiv), Ph 3 P (2.0 equiv), DIAD (2.0 equiv), toluene, 23 °C 12 h; f) Grubb's II (0.06 equiv), CH 2 C1 2 , 120 °C MW, 3 x 45 min; g) HFIP
  • an ⁇ , ⁇ -conjugated oxime is systematically better than the saturated one (Bl vs B2).
  • An additional methylene at the ⁇ position (B3) or ⁇ position (B4) as well as a hydroxyl group at the ⁇ position (B5) are generally well tolerated with the combinations A1B3C4D1 (entry 35), A1B4C4D1 (entry 38) and A1B5C1D1 (entry 40) being amongst the fittest ligand from the library.
  • the upper part of the macrocycle there was generally little difference between the activity of compounds having the chiral methyl group (CI) or a simple primary ester (C4).
  • the co-crystal structure of the N-terminal part HSP90 bound to radicicol (lbgq, Figure 1 , panels A) [36 ' is very similar to the structure of apo-HSP90(lyer) [37) . Crystal structures have also been reported for the functionally related ER chaperone GRP94 (l uOz) 1381 again showing a similar conformation of the ATP-binding pocket of HSP90. Likewise, the co-crystal structure of several resorcylide analogs of radicicol with HSP90 have also been reported to bind to a similar conformation of HSP90.
  • This rearrangement creates a large lyophylic pocket at the interface of the side chains of Met98, Leul 03, Phel38 and Trpl62 with the piperidine moiety sandwiched between the ar l moiety of Th l 2 and the side chains of Met98.
  • the rearrangement thus creates the opportunity for favorable interactions with the oxime substituent and hence, a rational for the enhancements in activity of the pochoximes as well as the preference of lypophilic groups on the hydoxylamine such a piperidine amides.
  • substitution at the allylic position such as in compounds which include fragment B4 and BS should point towards the solvent.
  • Compound IAIBSCI DI bearing a hydroxyl substitution at the allylic position (carbon 6) was deemed most interesting as it should improve aqueous solubility relatively to pochoximes A, B, and C and provide a handle to label the inhibitor with a marker or affinity tag.
  • This compound was prepared as a mixture of four diastereoisomers (two oxime geometries with either stereochemistry at carbon 6) which proved to be separable by HPLC.
  • compound 6 bearing a silyl protecting group on the allylic hydroxyl group was prepared according to a previously developed protocol (see supplemental information for detailed synthetic protocols). 1291 As shown in scheme 4, selective silyl deprotection of 6 using TBAF afforded 7 onto which was introduce a short linker via alkylation, azide displacement and reduction to afford amine 9. Labeling of 9 with Cy3 followed by EOM deprotection afforded pochoxime-Cy3 conjugate 10. Alternatively, compound 7 was labeled with biotin via a four step sequence involving coupling to a short PEG linker, Fmoc deprotection, coupling to biotin and global deprotection with TFA.
  • Reagents and conditions a) TBAF (1.5 equiv), THF, 0-23 °C, 3 h, 88%; b) NaH (7.2 equiv), 0 °C, then Bu 4 NI (1.1 equiv) MsO(CH 2 )3Br (4.7 equiv), 0-40 °C, 3 h; c) NaN 3 (1 1 equiv), DMSO, 60 °C, 2 h, 50 % over two steps; d) Ph 3 P (2.0 equiv), THF H 2 0 (9: 1) 40 °C, 24 h, 54%; e) Cy-3 (1.5 equiv), TNTU (1.35 equiv), Pr 2 EtN (3.0 equiv) 0-23 °C, 1 h, 95%; f) PS-SO3H (10 equiv), MeOH, 40 °C, 2 h, >90%; g) FmocAEEA-OH (
  • Reagents and conditions a) ClCH 2 COOH (4.0 equiv), PPh 3 (4.4 equiv), DIAD (4.4 equiv), THF, 0 - 23 °C, 14 h, 77%; b) HSCH 2 CH 2 NH 2 (4.0 equiv), pyridine (2.0 mL), Et 3 N (1.0 mL) MeOH, 45 °C, 24 h, 83%.
  • azide 8 was obtained following the same procedure as for azide 2,.
  • Glycopochoxime derivative 11 was prepared following the same procedure as for the synthesis of compound 5. The crude product was purified by HPLC HPLC [Agilent Zorbax Eclipse XDB-C18 9.4 mm x 25 mm column; flow rate 3.0 mL/min; linear gradient from 80% to 40% H 2 0 (0.01% TFA) in acetonitrile (0.01% TFA)] to give thio glycosides 11 (Z-isomer: 4.7 mg; E-isomer: 5.9 mg).
  • ⁇ /-pochoxime F stands as the most potent Hsp90 ligand in the pochoxime series (14 nM), which may be rationalized by the formation of a productive hydrogen bond to an aspartic acid residue in Hsp90.
  • the pochoxime-glucose conjugate As-14(6-5) was shown to be a potent Hsp90 ligand (32 nM) and may be useful to direct the inhibitor to metabolically demanding malignant cells by an active uptake mechanism.
  • As-6a(6-R) Synthesis of the acylated compound As-6a(6-/?): A solution of ester As-la (79 mg, 0.224 mmol, 1.5 equiv) in anhydrous THF (1 .5 mL) at -78 °C was treated with freshly prepared LDA (0.352 M, 0.352 mmol, 2.2 equiv) via cannula. After 25 minutes, a solution of Weinreb amide R- As-2 (45 mg, 0.144 mmol, 1.0 equiv) in THF (1.5 mL) at -78 °C was added by syringe.
  • As-7a(6-R) Synthesis of As-7a(6- .).
  • As-6a(6- ?)I 10.0 mg, 0.017 mmol, 1.0 equiv
  • isopropanol 1.0 mL
  • sulfonic acid resin 33.6 mg, 0.102 mmol, 6.0 equiv, 3.0 mmol/g
  • CH 2 CI 2 5.0 mL
  • MeOH 5.0 mL
  • TBS- S-As-4 Synthesis of protected aldol adduct TBS-S-As ⁇ .
  • S-As-4 173.5 mg, 0.867 mmol, 1.0 equiv
  • imidazole 94.45 mg, 1.387 mmol, 1.5 equiv
  • TBSCI 196 mg, 1.3 mmol, 1.3 equiv
  • the reaction mixture was stirred at the same temperature for 16 hours. After evaporation of the solvent, the residue was purified by flash chromatography (silica gel, 90/10 petroleum ether/EtOAc) to give TBS- ⁇ -As-4 in 97% yield (252 mg).
  • As-7a(6-S) Synthesis of As-7a(6-S .
  • As-6a(6-S)I 12.2 mg, 0.021 mmol, 1.0 equiv
  • isopropanol 1.0 mL
  • sulfonic acid resin 41 mg, 0.126 mmol, 6.0 equiv, 3.0 mmol/g
  • the reaction mixture was filtered and the resin rinsed with CH 2 CI2 (5.0 mL) and MeOH (5.0 mL). After removal of solvents under reduced pressure, the residue was purified by prep.
  • the crude product was purified by HPLC (Agilent 1 100 series HPLC equipped with DAD and with a Agilent ZORBAX Eclipse XDB-C18 (4.6 x 300 mm, 5 ⁇ ) column (linear gradient from 70% H20 0.1 % TFA 30% MeCN 0.1 % TFA to 50% H20 0.1% TFA 50% MeCN 0.1% TFA in 35 minutes with a flow rate of 2.0 mL/min) to give thio glycosides As-14(6-i?) in 52% over two steps (Z-isomer: 9.4 mg; E-isomer: 1 1.8 mg).
  • reaction mixture was then diluted with 10 mL H 2 0, lyophilized to give amine As-13(6-.K) in a 62% yield (5.0 mg) and purified by HPLC (Agilent 1 100 series HPLC equipped with DAD and with a Agilent ZORBAX Eclipse XDB-C18 (4.6 x 300 mm, 5 ⁇ ) column (linear gradient from 82% H20 0.1% TFA 18% MeCN 0.1% TFA to 64% H20 0.1% TFA 36% MeCN 0.1% TFA in 35 minutes with a flow rate of 2.0 mL/min).
  • HPLC Alent 1 100 series HPLC equipped with DAD and with a Agilent ZORBAX Eclipse XDB-C18 (4.6 x 300 mm, 5 ⁇ ) column (linear gradient from 82% H20 0.1% TFA 18% MeCN 0.1% TFA to 64% H20 0.1% TFA 36% MeCN 0.1% TFA in 35 minutes with a flow rate of 2.0 mL/min).
  • the crude acetyl derivative was dissolved in methanol (3.0 mL) and PS-SO3H (56 mg, 0.17 mmol, 10.0 equiv, 3.0 mmol/g) was added and stirred at 23 °C for 16 hours.
  • the reaction mixture was filtered, and evaporated under vacuo.
  • the crude product was purified by HPLC (Agilent 1 100 series HPLC equipped with DAD and with a Agilent ZORBAX Eclipse XDB-C18 (4.6 x 300 mm, 5 ⁇ ) column (linear gradient from 70% H20 0.1 % TFA 30% MeCN 0.1% TFA to 50% H20 0.1% TFA 50% MeCN 0.1% TFA in 35 minutes with a flow rate of 2.0 mL/min).
  • the conformational profile of the pochoxime derivatives were analyzed using the approach known to one skilled in the art.
  • Each molecule was simulated by molecular dynamics with the Merck Molecular Force Field (MMFF94) in the CHARMM program, version c31bl .
  • a dielectric constant of 80 was used to simulate the effect of solvent in a simple way.
  • the simulations were carried out at 1000 K during 10 ns and 2000 frames were extracted from the trajectory at 10 ps intervals. The high temperature was used to ensure that conformational energy barriers were crossed. Each frame was minimized by 2000 steps of the steepest descent (SD) algorithm in CHARM, and the MMFF energy was calculated. The resulting 2000 conformations were clustered to determine the main conformations.
  • SD steepest descent
  • the 6 new pochoximes, as well as the two ligands present in PDB ID 3INW and 3INX, and radicicol were all docked using two separate series of docking runs.
  • docking software were fed with the bioactive conformation for radicicol and the 3INW and 3 ⁇ ligands, and with the P-shape conformer for the new pochoximes.
  • all docking programs were fed with the bioactive L-shape conformer for all the ligands.
  • Fluoresceine-GA was purchased from InvivoGen and dissolved in DMSO to form a 1 mM solution.
  • HSP90 was purchased from Stressgen (SPP-776F).
  • the assay buffer contained
  • mP 1000 x [(IS-ISB) - (Ip- IPB)]/ [(IS-ISB) + P-IPB)], where Is is the parallel emission intensity, lp is the perpendicular emission intensity and Ise and IPB are the values for the background.
  • HER2+ BT474 breast carcinoma cells were cultured in DMEM/F12 media, supplemented with 10% FBS.
  • Log-phase growing BT474 cells were seeded in 96 well plates at 1.5X10E4 per well. At this cell density, BT474 is expected to reach confluency about 70-80% in 3 days.
  • Different dilutions of compounds or vehicle in 200 ⁇ concentration range 0.004-10 ⁇ were added to the cells and incubated for 72 hours. Upon completion of the incubation, media were gently removed by suction and 100 ⁇ of ATPlite solution (Perkin Elmer) was added in each well.
  • Viable cells were measured by detecting luminescence generated from reaction of ATPlite solution and ATP in the cells using a 96-well microplate luminescence reader. Relative luminescence light unit is correlated to the amount of ATP in viable cells. The assays were performed in duplicates. IC50 was calculated using XLfit. The IC 50 shown in Table 4 below is the average IC50 from three independent experiments. Table 4. IC50 of the Present Compounds
  • IC 50 values are shown in Table 5 below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)

Abstract

Cette invention concerne des nouveaux dérivés, analogues et intermédiaires de produits naturels - radicicol, pochonines, pochoximes - et leurs synthèses. Elle concerne également une composition pharmaceutique renfermant le présent composé et l'utilisation de ce dernier en tant qu'inhibiteur des kinases et de la famille d'enzymes connue sou l'appellation de protéine de choc thermique 90 (HSP90).
PCT/IB2011/002796 2010-10-22 2011-10-24 Dérivés de pochoxime convenant pour le traitement de pathologies en rapport avec hsp90 WO2012052843A1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
RU2013122898/04A RU2013122898A (ru) 2010-10-22 2011-10-24 Похоксимовые конъюгаты, применимые для лечения связанных с hsp90 патологий, композиция и способ лечения с их помощью
US13/880,878 US20140031302A1 (en) 2010-10-22 2011-10-24 Pochoxime conjugates useful for the treatment of hsp90 related pathologies
JP2013534404A JP2013543840A (ja) 2010-10-22 2011-10-24 Ｈｓｐ９０関連病態の治療のために有用なポコキシム複合物
AU2011319685A AU2011319685B2 (en) 2010-10-22 2011-10-24 Pochoxime conjugates useful for the treatment of HSP90 related pathologies
KR1020137012551A KR20140021520A (ko) 2010-10-22 2011-10-24 Hsp90 관련 질환의 치료에 유용한 포코옥심 컨쥬게이트
BR112013009614A BR112013009614A2 (pt) 2010-10-22 2011-10-24 conjugados de pochoxime úteis para o tratamento de patologias relacionadas à hsp90
CN2011800601830A CN103370311A (zh) 2010-10-22 2011-10-24 用于治疗HSP90相关病状的Pochoxime缀合物
CA2812320A CA2812320A1 (fr) 2010-10-22 2011-10-24 Derives de pochoxime convenant pour le traitement de pathologies en rapport avec hsp90
EP11797116.8A EP2630132A1 (fr) 2010-10-22 2011-10-24 Dérivés de pochoxime convenant pour le traitement de pathologies en rapport avec hsp90
IL225371A IL225371A0 (en) 2010-10-22 2013-03-20 Focoxim conjugates are useful for the treatment of pathologies related to 90hsp
US14/611,978 US20150374680A1 (en) 2010-10-22 2015-02-02 Pochoxime conjugates useful for the treatment of hsp90 related pathologies
US15/250,742 US20170174669A1 (en) 2010-10-22 2016-08-29 Pochoxime conjugates useful for the treatment of hsp90 related pathologies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40588210P 2010-10-22 2010-10-22
US61/405,882 2010-10-22

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/880,878 A-371-Of-International US20140031302A1 (en) 2010-10-22 2011-10-24 Pochoxime conjugates useful for the treatment of hsp90 related pathologies
US14/611,978 Continuation US20150374680A1 (en) 2010-10-22 2015-02-02 Pochoxime conjugates useful for the treatment of hsp90 related pathologies

Publications (1)

Publication Number Publication Date
WO2012052843A1 true WO2012052843A1 (fr) 2012-04-26

Family

ID=45350425

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/002796 WO2012052843A1 (fr) 2010-10-22 2011-10-24 Dérivés de pochoxime convenant pour le traitement de pathologies en rapport avec hsp90

Country Status (11)

Country Link
US (3) US20140031302A1 (fr)
EP (1) EP2630132A1 (fr)
JP (2) JP2013543840A (fr)
KR (1) KR20140021520A (fr)
CN (2) CN103370311A (fr)
AU (1) AU2011319685B2 (fr)
BR (1) BR112013009614A2 (fr)
CA (1) CA2812320A1 (fr)
IL (1) IL225371A0 (fr)
RU (1) RU2013122898A (fr)
WO (1) WO2012052843A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015038649A1 (fr) 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Thérapeutique ciblée
US9956293B2 (en) 2014-03-18 2018-05-01 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US10117944B2 (en) 2014-01-29 2018-11-06 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US10232049B2 (en) 2014-03-03 2019-03-19 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US10376598B2 (en) 2013-10-28 2019-08-13 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US10722525B2 (en) 2012-04-16 2020-07-28 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US11377447B2 (en) 2017-06-20 2022-07-05 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US11491145B2 (en) 2017-06-20 2022-11-08 Madrigal Pharmaceuticals, Inc. Combination therapies comprising targeted therapeutics

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3292116T3 (da) 2015-02-02 2022-01-10 Valo Health Inc 3-aryl-4-amido-bicykliske [4,5,0]hydroxamsyrer som hdac-inhibitorer
WO2016126726A1 (fr) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Acides hydroxamiques bicycliques [4,6,0] en tant qu'inhibiteurs hdac6
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
WO2022082108A1 (fr) * 2020-10-16 2022-04-21 The Brigham And Women's Hospital, Inc. Compositions pour induire une immunité tumorale et réduire la tolérance aux médicaments

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
WO2002002123A1 (fr) 2000-06-29 2002-01-10 Trustees Of Boston University Emploi de la geldanamycine et de composes associes pour la prophylaxie ou le traitement de troubles fibrogeniques
WO2009091921A1 (fr) * 2008-01-15 2009-07-23 Universite De Strasbourg Synthèse de lactones d'acide résorcylique utiles en tant qu'agents thérapeutiques

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861156A (en) * 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
ES2267149T3 (es) * 1996-08-30 2007-03-01 University Of Hawaii Nuevos derivados de criptoficina como agentes antineoplasicos.
EP0887351A4 (fr) * 1996-12-13 2001-06-06 Kyowa Hakko Kogyo Kk Derives dc 107 (2)
ITRM20010079A1 (it) * 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
TWI381852B (zh) * 2005-09-27 2013-01-11 Sigma Tau Ind Farmaceuti 生物素二胺基衍生物類及其與大環螯合劑之共軛物
US8329683B2 (en) * 2006-06-02 2012-12-11 Nexgenix Pharmaceuticals, Llc Treatment of neurofibromatosis with radicicol and its derivatives
ES2651019T3 (es) * 2006-08-11 2018-01-23 Universite De Strasbourg Compuestos macrocíclicos útiles como inhibidores de cinasas y de HSP90
CN102015673B (zh) * 2008-02-21 2014-10-29 昂科协同公司 用作治疗剂的大环前药化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
WO2002002123A1 (fr) 2000-06-29 2002-01-10 Trustees Of Boston University Emploi de la geldanamycine et de composes associes pour la prophylaxie ou le traitement de troubles fibrogeniques
WO2009091921A1 (fr) * 2008-01-15 2009-07-23 Universite De Strasbourg Synthèse de lactones d'acide résorcylique utiles en tant qu'agents thérapeutiques

Non-Patent Citations (71)

* Cited by examiner, † Cited by third party
Title
"Pharmaceutical Dosage Forms", 1980, MARCEL DECKER
"Remington's Pharmaceutical Sciences", MACK PUBLISHING CO.
"Theilheimer's Synthetic Methods of Organic Chemistry", vol. 1-45, 1991
"Water- insoluble drug formulation", 2000, INTERPHARM PRESS
A. SITTLER; R. LURZ; G. LUEDER; J. PRILLER; H. LEHRACH; M. K. HAYER-HARTL; F. U. HARTL; E. E. WANKER, HUM. MOL. GENET., vol. 10, 2001, pages 1307 - 1315
ANGEW. CHEM., vol. 119, 2008, pages 7023 - 7026
ANGEW. CHEM., vol. 120, 2008, pages 4504 - 4507
BEILSTEIN HANDBOOK OF ORGANIC CHEMISTRY
BROOKS, B. R.; BRUCCOLERI, R. E.; OLAFSON, B. D.; STATES, D. J.; SWAMINATHAN, S.; KARPLUS, M., J.COMPUT.CHEM, vol. 4, 1983, pages 187 - 217
C. WANG; S. BARLUENGA; G. K. KORIPELLY; J. G. FONTAINE; R. CHEN; J. C. YU; X. SHEN; J. C. CHABALA; J. V. HECK; A. RUBENSTEIN, BIOORG. MED. CHEM. LETT., vol. 19, 2009, pages 3836 - 3840
CAREY; SUNDBERG: "ADVANCED ORGANIC CHEMISTY", 1992, PLENUM
E. MCDONALD; K. JONES; P. A. BROUGH; M. J. DRYSDALE; P. WORKMAN, CURR. TOP. MED. CHEM., vol. 6, 2006, pages 1193 - 1203
E. MOULIN; S. BARLUENGA; F. TOTZKE; N. WINSSINGER, CHEM. EUR. J, vol. 12, 2006, pages 8819 - 8834
E. MOULIN; V. ZOETE; S. BARLUENGA; M. KARPLUS; N. WINSSINGER, J AM. CHEM. SOC., vol. 127, 2005, pages 6999 - 7004
FEISER: "Reagents for Organic Synthesis", vol. 1-21, WILEY INTERSCIENCE
G. CHIOSIS; E. CALDAS LOPES; D. SOLIT, CURR OPIN LNVESTIG DRUGS, vol. 7, 2006, pages 534 - 541
G. CHIOSIS; Y. KANG; W. SUN, EXPERT OPIN. DRUG DISCOVERY, vol. 3, 2008, pages 99 - 114
GREEN; WUTS: "PROTECTIVE GROUPS IN ORGANIC SYNTHESIS", 1991, WILEY
GREENE ET AL.: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY AND SONS
GREENE ET AL.: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS
GREENE; WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY INTERSCIENCE
GROSDIDIER A; ZOETE V; MICHIELIN O., J COMPUT CHEM., vol. 30, no. 13, October 2009 (2009-10-01), pages 2021 - 30
HALGREN, T. A., J. COMPUT. CHEM, vol. 17, 1996, pages 553 - 586
HALGREN, T. A., J. COMPUT. CHEM., vol. 17, 1996, pages 490 - 519
HALGREN, T. A., J.COMPUT.CHEM., vol. 17, 1996, pages 616 - 641
HALGREN, T. A., JCOMPUT.CHEM., no. 17, 1996, pages 520 - 552
HALGREN, T. A.; NACHBAR, R. B., JCOMPUT. CHEM., vol. 17, 1996, pages 587 - 615
HARRISON ET AL.: "Compendium of Synthetic Organic Methods", vol. 1-8, JOHN WILEY AND SONS
J. KIM; S. FELTS; L. LLAUGER; H. HE; H. HUEZO; N. ROSEN; G. CHIOSIS, J BIOMOL. SCREEN., vol. 9, 2004, pages 375 - 381
J. R. SYDOR; E. NORMANT; C. S. PIEN; J. R. PORTER; J. GE; L. GRENIER; R. H. PAK; J. A. ALI; M. S. DEMBSKI; J. HUDAK, PROC. NAIL. ACAD. SCI. U S A, vol. 103, 2006, pages 17408 - 17413
J. W. RICE; J. M. VEAL; R. P. FADDEN; A. F. BARABASZ; J. M. PARTRIDGE; T. E. BARTA; L. G. DUBOIS; K. H. HUANG; S. R. MABBETT; M. A, ARTHRITIS RHEUM., vol. 58, 2008, pages 3765 - 3775
K. H. HUANG; J. M. VEAL; R. P. FADDEN; J. W. RICE; J. EAVES; J. P. STRACHAN; A. F. BARABASZ; B. E. FOLEY; T. E. BARTA; W. MA, J MED. CHEM., vol. 52, 2009, pages 4288 - 4305
K. L. SOLDANO; A. JIVAN; C. V. NICCHITTA; D. T. GEWIRTH, J BIOL. CHEM., vol. 278, 2003, pages 48330 - 48338
K. LUNDGREN; H. ZHANG; J. BREKKEN; N. HUSER; R. E. POWELL; N. TIMPLE; D. J. BUSCH; L. NEELY; J. L. SENSINTAFFAR; Y. C. YANG, MOL. CANCER THER., vol. 8, 2009, pages 921 - 929
K. RICHTER; S. MOSER; F. HAGN; R. FRIEDRICH; O. HAINZL; M. HELLER; S. SCHLEE; H. KESSLER; J. REINSTEIN; J. BUCHNER, 1 BIOL. CHEM., vol. 281, 2006, pages 11301 - 11311
L. NECKERS; K. NECKERS, EXPERT. OPIN. EMERG. DRUGS, vol. 10, 2005, pages 137 - 149
L. NECKERS; T. W. SCHULTE; E. MIMNAUGH, INVEST. NEW DRUGS, vol. 17, 1999, pages 361 - 373
L. WHITESELL; S. L. LINDQUIST, NAT. REV. CANCER, vol. 5, 2005, pages 761 - 772
L. WRIGHT; X. BARRIL; B. DYMOCK; L. SHERIDAN; A. SURGENOR; M. BESWICK; M. DRYSDALE; A. COLLIER; A. MASSEY; N. DAVIES, CHEM. BIOL., vol. 11, 2004, pages 775 - 785
LAROCK: "Comprehensive Organic Transformations", 1989, VCH PUBLISHERS
M. SCHOLL; S. DING; C. W. LEE; R. H. GRUBBS, ORG. LETT., vol. 1, 1999, pages 953 - 956
M. SPICHTY; A. TALY; F. HAGN; H. KESSLER; S. BARLUENGA; N. WINSSINGER; M. KARPLUS, BIOPHYS. CHEM., vol. 143, 2009, pages 111 - 123
M. WAZA; H. ADACHI; M. KATSUNO; M. MINAMIYAMA; C. SANG; F. TANAKA; A. INUKAI; M. DOYU; G. SOBUE, NAT. MED., vol. 11, 2005, pages 1088 - 1095
MARCH: "Advanced Organic Chemistry", 1991, WILEY INTERSCIENCE
MARCH: "ADVANCED ORGANIC CHEMISTRY", 1992, WILEY
MORRIS GM; HUEY R; LINDSTROM W; SANNER MF; BELEW RK; GOODSELL DS; OLSON AJ.J, COMPUT CHEM., vol. 30, no. 16, December 2009 (2009-12-01), pages 2785 - 91
N. PROISY; S. Y. SHARP; K. BOXALL; S. CONNELLY; S. M. ROE; C. PRODROMOU; A. M. SLAWIN; L. H. PEARL; P. WORKMAN; C. J. MOODY, CHEM. BIOL., vol. 13, 2006, pages 1203 - 1215
P. K. AULUCK; N. M. BONINI, NAT. MED., vol. 8, 2002, pages 1185 - 1186
P. WORKMAN; F. BURROWS; L. NECKERS; N. ROSEN, ANN. N.Y. ACAD. SCI., vol. 1113, 2007, pages 202 - 216
P. Y. DAKAS; S. BARLUENGA; F. TOTZKE; U. ZIRRGIEBEL; N. WINSSINGER, ANGEW. CHEM. INT. ED. ENGL., vol. 46, 2007, pages 6899 - 6902
PAQUETTE: "Encyclopedia of Reagents for Organic Synthesis", 1995, JOHN WILEY & SONS
R. GELLER; M. VIGNUZZI; R. ANDINO; J. FRYDMAN, GENES DEV., vol. 21, 2007, pages 195 - 205
S. A. ECCLES; A. MASSEY; F. I. RAYNAUD; S. Y. SHARP; G. BOX; M. VALENTI; L. PATTERSON; A. DE HAVEN BRANDON; S. GOWAN; F. BOXALL, CANCER RES., vol. 68, 2008, pages 2850 - 2860
S. BARLUENGA; C. WANG; J. G. FONTAINE; K. AOUADI; K. BEEBE; S. TSUTSUMI; L. NECKERS; N. WINSSINGER, ANGEW. CHEM. INT. ED. ENGL., vol. 47, 2008, pages 4432 - 4435
S. CHANDARLAPATY; A. SAWAI; Q. YE; A. SCOTT; M. SILINSKI; K. HUANG; P. FADDEN; J. PARTDRIGE; S. HALL; P. STEED, CLIN. CANCER RES., vol. 14, 2008, pages 240 - 248
S. M. ROE; C. PRODROMOU; R. O'BRIEN; J. E. LADBURY; P. W. PIPER; L. H. PEARL, J MED. CHEM., vol. 42, 1999, pages 260 - 266
S. MODI; A. T. STOPECK; M. S. GORDON; D. MENDELSON; D. B. SOLIT; R. BAGATELL; W. MA; J. WHELER; N. ROSEN; L. NORTON, J. CLIN. ONCOL., vol. 25, 2007, pages 5410 - 5417
S. SOGA; L. M. NECKERS; T. W. SCHULTE; Y. SHIOTSU; K. AKASAKA; H. NARUMI; T. AGATSUMA; Y. IKUINA; C. MURAKATA; T. TAMAOKI, CANCER RES., vol. 59, 1999, pages 2931 - 2938
S. V. SHARMA; T. AGATSUMA; H. NAKANO, ONCOGENE, vol. 16, 1998, pages 2639 - 2645
S. Y. SHARP; C. PRODROMOU; K. BOXALL; M. V. POWERS; J. L. HOLMES; G. BOX; T. P. MATTHEWS; K.-M. J. CHEUNG; A. KALUSA; K. JAMES, MOL. CANCER THER., vol. 6, 2007, pages 1198 - 1211
SOFIA BARLUENGA ET AL: "Inhibition of HSP90 with Pochoximes: SAR and Structure-Based Insights", CHEMBIOCHEM, vol. 10, no. 17, 23 November 2009 (2009-11-23), pages 2753 - 2759, XP055018604, ISSN: 1439-4227, DOI: 10.1002/cbic.200900494 *
T. E. BARTA; J. M. VEAL; J. W. RICE; J. M. PARTRIDGE; R. P. FADDEN; W. MA; M. JENKS; L. GENG; G. J. HANSON; K. H. HUANG, BIOORG. MED. CHEM. LETT, vol. 18, 2008, pages 3517 - 3521
T. TALDONE; A. GOZMAN; R. MAHARAJ; G. CHIOSIS, CURR. OPIN. PHARMACOL., vol. 8, 2008, pages 370 - 374
T. TALDONE; W. SUN; G. CHIOSIS, BIOORG. MED CHEM. LETT., vol. 17, 2009, pages 2225 - 2235
T. W. SCHULTE; S. AKINAGA; S. SOGA; W. SULLIVAN; B. STENSGARD; D. TOFT; L. M. NECKERS, CELL STRESS CHAPERONES, vol. 3, 1998, pages 100 - 108
TROST ET AL.: "Comprehensive Organic Synthesis", 1991, PERGAMON PRESS
TROTT 0; OLSON AJ.J, COMPUT CHEM., vol. 31, no. 2, 30 January 2010 (2010-01-30), pages 455 - 61
W. LUO; A. RODINA; G. CHIOSIS, BMC NEUROSCI., vol. 9, no. 2, 2008, pages S7
W. LUO; F. DOU; A. RODINA; S. CHIP; J. KIM; Q. ZHAO; K. MOULICK; J. AGUIRRE; N. WU; P. GREENGARD, PROC. NATL. ACAD. SCI. USA, vol. 104, 2007, pages 9511 - 9516
W. XU; E. MIMNAUGH; M. F. ROSSER; C. NICCHITTA; M. MARCU; Y. YARDEN; L. NECKERS, J. BIOL. CHEM., vol. 276, 2001, pages 3702 - 3708
Y. IKUINA; N. AMISHIRO; M. MIYATA; H. NARUMI; H. OGAWA; T. AKIYAMA; Y. SHIOTSU; S. AKINAGA; C. MURAKATA, J. MED. CHEM., vol. 46, 2003, pages 2534 - 2541

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10722525B2 (en) 2012-04-16 2020-07-28 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
WO2015038649A1 (fr) 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Thérapeutique ciblée
EP3035938A4 (fr) * 2013-09-10 2017-04-19 Madrigal Pharmaceuticals, Inc. Thérapeutique ciblée
US10828315B2 (en) 2013-09-10 2020-11-10 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
EP3738594A1 (fr) * 2013-09-10 2020-11-18 Madrigal Pharmaceuticals, Inc. Agents thérapeutiques ciblés ayant un ligand hsp90 comme moietie de liaison
US10376598B2 (en) 2013-10-28 2019-08-13 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US10117944B2 (en) 2014-01-29 2018-11-06 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US10232049B2 (en) 2014-03-03 2019-03-19 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US10675360B2 (en) 2014-03-03 2020-06-09 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US9956293B2 (en) 2014-03-18 2018-05-01 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US11377447B2 (en) 2017-06-20 2022-07-05 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US11491145B2 (en) 2017-06-20 2022-11-08 Madrigal Pharmaceuticals, Inc. Combination therapies comprising targeted therapeutics

Also Published As

Publication number Publication date
CN107011311A (zh) 2017-08-04
AU2011319685B2 (en) 2016-02-04
JP2013543840A (ja) 2013-12-09
EP2630132A1 (fr) 2013-08-28
US20140031302A1 (en) 2014-01-30
US20150374680A1 (en) 2015-12-31
AU2011319685A1 (en) 2013-04-11
CN103370311A (zh) 2013-10-23
JP2017039730A (ja) 2017-02-23
IL225371A0 (en) 2013-06-27
KR20140021520A (ko) 2014-02-20
BR112013009614A2 (pt) 2016-07-19
US20170174669A1 (en) 2017-06-22
CA2812320A1 (fr) 2012-04-26
RU2013122898A (ru) 2014-11-27

Similar Documents

Publication Publication Date Title
AU2011319685B2 (en) Pochoxime conjugates useful for the treatment of HSP90 related pathologies
ES2651019T3 (es) Compuestos macrocíclicos útiles como inhibidores de cinasas y de HSP90
KR101835252B1 (ko) 치료제로서 유용한 레조르실산 락톤의 합성
KR20160062170A (ko) 융합된 헤테로사이클릭 화합물, 이의 제조 방법, 약학적 조성물, 및 그 용도
US20240189320A1 (en) Highly active sting protein agonist compound
US8513440B2 (en) Compositions and methods comprising analogues of radicicol A
KR101640951B1 (ko) 치료제로서 유용한 거대고리 프로드러그
US20240217978A1 (en) COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
US20140135290A1 (en) Macrocyclic prodrug compounds useful as therapeutics

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11797116

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 225371

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2812320

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2011319685

Country of ref document: AU

Date of ref document: 20111024

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013534404

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011797116

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011797116

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20137012551

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013122898

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13880878

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013009614

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013009614

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130419